LT3466949T - Triciklinis junginys kaip priešvėžinis agentas - Google Patents

Triciklinis junginys kaip priešvėžinis agentas

Info

Publication number
LT3466949T
LT3466949T LTEP18192207.1T LT18192207T LT3466949T LT 3466949 T LT3466949 T LT 3466949T LT 18192207 T LT18192207 T LT 18192207T LT 3466949 T LT3466949 T LT 3466949T
Authority
LT
Lithuania
Prior art keywords
agent
tricycle compound
tricycle
compound
Prior art date
Application number
LTEP18192207.1T
Other languages
English (en)
Lithuanian (lt)
Inventor
Derek J. Norris
George V. Delucca
Ashvinikumar V. Gavai
Claude A. Quesnelle
Patrice Gill
Daniel O`MALLEY
Wayne Vaccaro
Francis Y. Lee
Mikkel V. DEBENEDETTO
Andrew P. Degnan
Haiquan Fang
Matthew D. Hill
Hong Huang
William D. Schmitz
Starrett, Jr
Wen-Ching Han
John S. Tokarski
Sunil Kumar MANDAL
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of LT3466949T publication Critical patent/LT3466949T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
LTEP18192207.1T 2013-12-24 2014-12-23 Triciklinis junginys kaip priešvėžinis agentas LT3466949T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361920500P 2013-12-24 2013-12-24

Publications (1)

Publication Number Publication Date
LT3466949T true LT3466949T (lt) 2021-03-25

Family

ID=52293305

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP18192207.1T LT3466949T (lt) 2013-12-24 2014-12-23 Triciklinis junginys kaip priešvėžinis agentas
LTEP14824743.0T LT3087071T (lt) 2013-12-24 2014-12-23 Tricikliniai junginiai kaip priešvėžiniai agentai

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP14824743.0T LT3087071T (lt) 2013-12-24 2014-12-23 Tricikliniai junginiai kaip priešvėžiniai agentai

Country Status (34)

Country Link
US (1) US20160318928A1 (fr)
EP (2) EP3087071B1 (fr)
JP (2) JP6466456B2 (fr)
KR (1) KR102457145B1 (fr)
CN (2) CN108558871B (fr)
AR (2) AR099379A1 (fr)
AU (1) AU2014369982B2 (fr)
BR (1) BR112016013744B1 (fr)
CA (1) CA2934953C (fr)
CL (1) CL2016001629A1 (fr)
CY (2) CY1121076T1 (fr)
DK (2) DK3466949T3 (fr)
EA (2) EA201990240A1 (fr)
ES (2) ES2698998T3 (fr)
HR (2) HRP20181849T1 (fr)
HU (2) HUE054183T2 (fr)
IL (1) IL246359B (fr)
LT (2) LT3466949T (fr)
MA (1) MA39211B1 (fr)
MX (1) MX369491B (fr)
MY (1) MY176489A (fr)
NZ (1) NZ722326A (fr)
PE (1) PE20160844A1 (fr)
PH (1) PH12016500953A1 (fr)
PL (2) PL3466949T3 (fr)
PT (2) PT3466949T (fr)
RS (2) RS58014B1 (fr)
SG (1) SG11201605097SA (fr)
SI (2) SI3087071T1 (fr)
SM (2) SMT202100165T1 (fr)
TN (1) TN2016000238A1 (fr)
TW (2) TWI736517B (fr)
UY (1) UY35916A (fr)
WO (1) WO2015100282A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6404838B2 (ja) 2013-02-27 2018-10-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ブロモドメイン阻害剤として有用なカルバゾール化合物
EP3066101B1 (fr) 2013-11-08 2020-07-29 Dana-Farber Cancer Institute, Inc. Polythérapie pour le traitement du cancer utilisant des inhibiteurs de protéine à bromodomaine et à domaine extra-terminal (bet)
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
HUE054183T2 (hu) * 2013-12-24 2021-08-30 Bristol Myers Squibb Co Triciklusos vegyület rákellenes szerekként
JP2017511801A (ja) * 2014-02-28 2017-04-27 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン ＢＥＴブロモドメイン阻害剤としての９Ｈ−ピリミド［４，５−ｂ］インドールおよび関連類似体
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EP3307740B1 (fr) 2015-05-12 2019-12-18 Bristol-Myers Squibb Company Composés 5h-pyrido[3,2-b]indole en tant qu'agents anticancéreux
CN116059219A (zh) 2015-07-16 2023-05-05 比奥克斯塞尔医疗股份有限公司 一种使用免疫调节治疗癌症的新颖方法
EP3355922A2 (fr) * 2015-10-02 2018-08-08 Dana Farber Cancer Institute, Inc. Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle
WO2017124934A1 (fr) * 2016-01-20 2017-07-27 宁波文达医药科技有限公司 Dérivé de carboline contenant de la phosphine servant d'inhibiteur de bromodomaine
JP6855505B2 (ja) * 2016-01-20 2021-04-07 ニンボー ウェンダ ファーマー テクノロジー エルティーディー． ブロモドメイン阻害剤としてのカルボリン誘導体
US20190040063A1 (en) * 2016-02-05 2019-02-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tricyclic compound for bromodomain-containing protein inhibitor and preparation pharmaceutical composition, and application thereof
MX390517B (es) 2016-03-01 2025-03-20 Corcept Therapeutics Inc Uso de moduladores del receptor de glucocorticoides para potenciar inhibidores de puntos de regulacion.
US10150754B2 (en) * 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN108069976A (zh) 2016-11-10 2018-05-25 山东罗欣药业集团股份有限公司 一种含氮大环类化合物、其制备方法、药物组合物及应用
CN109824693B (zh) * 2017-04-18 2020-12-08 四川大学 Brd4抑制剂及其在肿瘤治疗药物中的应用
WO2019080941A1 (fr) * 2017-10-27 2019-05-02 Jacobio-Beta Pharmaceuticals Co., Ltd. Nouveaux composés tricycliques
CN112513041B (zh) 2018-06-25 2022-05-10 北京加科思新药研发有限公司 三环化合物
CN108840868B (zh) * 2018-08-01 2019-10-18 上海山的实业有限公司 具有抗肿瘤活性的吲哚并吡啶酮类化合物的制备方法及应用
WO2020132046A1 (fr) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Méthodes de traitement du cancer comprenant l'administration d'un modulateur du récepteur des glucocorticoïdes et d'un agent chimiothérapeutique anticancéreux
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020200284A1 (fr) * 2019-04-04 2020-10-08 上海华汇拓医药科技有限公司 Procédé de préparation de composé tricyclique et son utilisation dans le domaine de la médecine
CN110003204B (zh) * 2019-04-30 2020-08-11 上海勋和医药科技有限公司 一种bet蛋白抑制剂、其制备方法及用途
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
TW202126638A (zh) 2019-09-30 2021-07-16 日商協和麒麟股份有限公司 Bet分解劑
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
CA3206066A1 (fr) * 2021-01-22 2022-07-28 Jingrui Biopharma Co., Ltd. Composes tricycliques en tant qu'agents anticancereux
AU2022227673A1 (en) * 2021-02-25 2023-08-17 Impact Biomedicines, Inc. Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
US12016847B2 (en) * 2021-03-12 2024-06-25 Bristol-Myers Squibb Company Methods of treating prostate cancer
AU2022270984A1 (en) * 2021-05-06 2023-11-23 Raziel Therapeutics Ltd. Crystalline carbazole derivative
WO2024099441A1 (fr) * 2022-11-11 2024-05-16 Jingrui Biopharma (Shandong) Co., Ltd. Dégradeur de protéine à bromodomaines et domaine extra-terminal (bet)

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3427093A (en) * 1992-01-15 1993-08-03 E.I. Du Pont De Nemours And Company Bridged heterocyclic fungicides
JP2007509045A (ja) 2003-10-18 2007-04-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 尿失禁および関連疾患の処置用のｇａｂａアゴニストとしての５−置換２−（フェニルメチル）チオ−４−フェニル−４ｈ−１，２，４−トリアゾール誘導体および関連化合物
EP1686949A2 (fr) * 2003-11-24 2006-08-09 Viropharma Incorporated Composes, compositions et procedes pour le traitement et la prophylaxie d'infections de l'hepatite c virale et de maladies associees
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
PL2559690T3 (pl) 2005-05-10 2016-09-30 Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
CA2612241C (fr) 2005-07-01 2018-11-06 Medarex, Inc. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
TWI382974B (zh) 2005-12-20 2013-01-21 英塞特公司 作為吲哚胺２，３-二氧化酶調節劑之ｎ-羥基甲脒基雜環化物
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
JP5319532B2 (ja) 2006-09-19 2013-10-16 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
EP1987839A1 (fr) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Anticorps monoclonal cytotoxique anti-LAG-3 et son utilisation pour le traitement ou la prévention d'un rejet de greffe d'organe et de maladies auto-immunes
CN101801413A (zh) 2007-07-12 2010-08-11 托勒克斯股份有限公司 采用gitr结合分子的联合疗法
EP2044949A1 (fr) 2007-10-05 2009-04-08 Immutep Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes
CN101932325B (zh) 2007-11-30 2014-05-28 新联基因公司 Ido抑制剂
FR2927330B1 (fr) 2008-02-07 2010-02-19 Sanofi Aventis Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP4209510B1 (fr) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
CN102325752B (zh) * 2008-12-19 2015-02-04 百时美施贵宝公司 咔唑和咔啉激酶抑制剂
PT3023438T (pt) 2009-09-03 2020-05-08 Merck Sharp & Dohme Anticorpos anti-gitr
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
EP2949670B1 (fr) 2009-12-10 2019-02-27 F. Hoffmann-La Roche AG Anticorps se liant de préférence au domaine extracellulaire 4 du csf1r humain et leur utilisation
EA201201191A1 (ru) 2010-02-26 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
KR101656548B1 (ko) 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
TWI503323B (zh) * 2010-03-29 2015-10-11 Oncotherapy Science Inc 三環化合物以及含此化合物之ｐｂｋ抑制劑
SMT201900074T1 (it) 2010-05-04 2019-02-28 Five Prime Therapeutics Inc Anticorpi che legano csf1r
EP2582698B1 (fr) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Hétérocycles à 5, 6 et 7 chaînons substitués, médicaments contenant ces composés et leur utilisation
SG10201912092VA (en) 2010-09-09 2020-02-27 Pfizer 4-1bb binding molecules
AU2011343712B2 (en) * 2010-12-16 2015-09-17 Genentech, Inc. Tricyclic PI3k inhibitor compounds and methods of use
US8580399B2 (en) * 2011-04-08 2013-11-12 Universal Display Corporation Substituted oligoazacarbazoles for light emitting diodes
NO2694640T3 (fr) 2011-04-15 2018-03-17
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
JP6012611B2 (ja) * 2011-09-28 2016-10-25 出光興産株式会社 有機エレクトロルミネッセンス素子用材料及びそれを用いた有機エレクトロルミネッセンス素子
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
EP2791174B1 (fr) 2011-12-15 2018-02-28 F. Hoffmann-La Roche AG Anticorps contre csf-1r humain et usages correspondants
CN104093740B (zh) 2012-02-06 2018-01-09 弗·哈夫曼-拉罗切有限公司 使用csf1r抑制剂的组合物和方法
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN104684582A (zh) 2012-08-31 2015-06-03 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
UA115576C2 (uk) * 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
JP6404838B2 (ja) * 2013-02-27 2018-10-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ブロモドメイン阻害剤として有用なカルバゾール化合物
JP6401773B2 (ja) * 2013-03-11 2018-10-10 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Ｂｅｔブロモドメイン阻害剤およびこれを用いる治療方法
HUE054183T2 (hu) * 2013-12-24 2021-08-30 Bristol Myers Squibb Co Triciklusos vegyület rákellenes szerekként

Also Published As

Publication number Publication date
CN106029663B (zh) 2018-06-01
MY176489A (en) 2020-08-12
WO2015100282A1 (fr) 2015-07-02
JP2017505762A (ja) 2017-02-23
AR099379A1 (es) 2016-07-20
EA032469B1 (ru) 2019-05-31
RS58014B1 (sr) 2019-02-28
RS61479B1 (sr) 2021-03-31
CN106029663A (zh) 2016-10-12
EP3087071A1 (fr) 2016-11-02
SMT202100165T1 (it) 2021-05-07
MX369491B (es) 2019-11-11
MA39211B1 (fr) 2019-01-31
BR112016013744A2 (fr) 2017-10-03
JP6466456B2 (ja) 2019-02-06
HUE054183T2 (hu) 2021-08-30
SG11201605097SA (en) 2016-07-28
KR102457145B1 (ko) 2022-10-19
DK3466949T3 (da) 2021-03-15
IL246359B (en) 2020-04-30
EA201990240A1 (ru) 2019-06-28
US20160318928A1 (en) 2016-11-03
CN108558871A (zh) 2018-09-21
PH12016500953A1 (en) 2016-06-27
TWI736517B (zh) 2021-08-21
EA201691070A1 (ru) 2016-11-30
JP2019070014A (ja) 2019-05-09
TW201609725A (zh) 2016-03-16
HUE041719T2 (hu) 2019-05-28
NZ722326A (en) 2019-09-27
CA2934953A1 (fr) 2015-07-02
BR112016013744B1 (pt) 2022-08-30
KR20160095168A (ko) 2016-08-10
CL2016001629A1 (es) 2017-02-17
IL246359A0 (en) 2016-08-31
TW202028203A (zh) 2020-08-01
EP3466949B1 (fr) 2020-12-23
JP6675501B2 (ja) 2020-04-01
MX2016007928A (es) 2016-08-03
EP3087071B1 (fr) 2018-09-05
DK3087071T3 (da) 2019-01-02
UY35916A (es) 2015-06-30
AU2014369982B2 (en) 2019-04-18
PE20160844A1 (es) 2016-09-03
CY1121076T1 (el) 2019-12-11
SMT201800643T1 (it) 2019-01-11
TN2016000238A1 (en) 2017-10-06
AU2014369982A1 (en) 2016-08-04
SI3466949T1 (sl) 2021-03-31
PT3087071T (pt) 2018-11-29
AR123996A2 (es) 2023-02-01
CA2934953C (fr) 2022-09-20
PL3466949T3 (pl) 2021-05-31
HRP20210212T8 (hr) 2021-08-20
CY1124061T1 (el) 2022-05-27
TWI726544B (zh) 2021-05-01
HRP20181849T1 (hr) 2018-12-28
PT3466949T (pt) 2021-02-25
HRP20210212T1 (hr) 2021-07-09
SI3087071T1 (sl) 2018-11-30
ES2698998T3 (es) 2019-02-06
PL3087071T3 (pl) 2019-03-29
LT3087071T (lt) 2018-11-12
MA39211A1 (fr) 2018-08-31
EP3466949A1 (fr) 2019-04-10
ES2857848T3 (es) 2021-09-29
CN108558871B (zh) 2022-02-18

Similar Documents

Publication Publication Date Title
LT3060041T (lt) Prostaciklino junginiai
CL2013001994S1 (es) Motocicleta
DK2970336T3 (da) Tetrahydropyrrolothiazinforbindelser
DK3466949T3 (da) Tricyklisk forbindelse som anticancermidler
EP2889350A4 (fr) Composition collante-adhésive
DK3022110T3 (da) Cykelsadel
CL2014000309S1 (es) Motocicleta
CL2014000108S1 (es) Motocicleta
DK3027750T3 (da) Biokatalytisk sammensætning
HRP20171890T1 (hr) Supstituirani imidazopiridazini
UA29891S (uk) Мотоцикл
SMT201700115B (it) COMPOSTI BICICLlCI
IL240904A0 (en) Azetidinyloxyphenylpyrrolidine compounds
DK2969723T3 (da) Trehjulede cykel
HRP20180618T1 (hr) Spojevi fluorfenilpirazola
DK2947066T3 (da) Phenoxyalkylaminforbindelse
EP2995538A4 (fr) Motocycle
CL2014000196S1 (es) Motocicleta
FR3011527B1 (fr) Guidon repliable
HRP20180722T1 (hr) Spoj benzotiofena
DK2969720T3 (da) Trehjulede cykel
ITMI20130606A1 (it) Composti naftoeterodiazolici disostituiti
TH1501000971A (th) สารประกอบพิแรโซโลพิริมิดีน
TH1401007838A (th) สารประกอบฟีนอกซิเอธิลไพเพอริดีน
TH1401007117A (th) สารประกอบเตตระไฮโดรไพราโซโลไพริมิดีน